Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, autoimmune disorders and infectious diseases, carries out a directed share issue of SEK 400 million to further advance the company’s industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials. The financing brings together a group of Nordic investors, with Swedbank Robur Ny Teknik, Ramsbury Invest and significant family offices, including those of Harald Mix and Robert Andreen, joining existing investors including Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano. For more information, see www.anocca.com.
HWF Advokater has advised Anocca in connection with the share issue.
